Does retatrutide raise HDL cholesterol?

No. A 2026 meta-analysis of randomized trials found no significant change in HDL cholesterol with retatrutide. The pooled difference from control groups was 0.01 mg/dL.

Can retatrutide replace a statin?

No. Retatrutide is investigational and is not FDA approved for any use. No trial has tested it against a statin, and no trial has shown that it prevents heart attacks or strokes.

Can retatrutide make blood pressure drop too low?

It can. In the TRIUMPH-2 trial published in The Lancet, hypotension occurred in 1% to 6% of people on retatrutide, depending on dose, versus less than 1% on placebo. People who take blood pressure medicine should discuss this risk with their clinician.

Is the drop in triglycerides caused by the drug or by weight loss?

The published trials cannot separate the two. People on retatrutide lost a large share of their body weight, and weight loss alone lowers triglycerides and blood pressure. A direct drug effect is possible but not proven.

Did the phase 3 trials report LDL cholesterol?

The Lilly press releases report non-HDL cholesterol and triglycerides, not LDL cholesterol. The abstracts of the published TRIUMPH-1 and TRIUMPH-2 papers give no lipid figures. The LDL figure in this article comes from a meta-analysis of earlier trials.

Does Retatrutide Lower Cholesterol and Blood Pressure?

The short answer: In trials, yes. A 2026 meta-analysis of randomized trials found retatrutide lowered LDL cholesterol by 13.10 mg/dL, triglycerides by 40.90 mg/dL, and systolic blood pressure by 6.79 mmHg compared with control groups. HDL cholesterol did not change, and the phase 2 obesity trial reported a dose-dependent rise in heart rate. Retatrutide is investigational and is not FDA approved, so nobody can be prescribed it for cholesterol or blood pressure.

How much did cholesterol and triglycerides change in phase 2?

Two phase 2 trials supply most of the peer-reviewed lipid data. One enrolled 338 adults with obesity and ran for 48 weeks (Jastreboff et al., NEJM 2023). The other enrolled 281 adults with type 2 diabetes and ran for 36 weeks (Rosenstock et al., Lancet 2023).

A 2026 meta-analysis of randomized trials pooled the published results. Compared with control groups, retatrutide lowered:

Total cholesterol by 21.88 mg/dL (95% CI 15.97 to 27.79)
LDL cholesterol by 13.10 mg/dL (95% CI 10.10 to 16.10)
Triglycerides by 40.90 mg/dL (95% CI 33.30 to 48.50)

HDL cholesterol did not move. The pooled difference was 0.01 mg/dL, which was not statistically significant.

Lilly scientists then ran a post hoc biomarker analysis of both phase 2 trials, published in Diabetes, Obesity and Metabolism in 2026. It reported placebo-adjusted changes of up to:

Non-HDL cholesterol: 21.0% lower in the diabetes trial and 26.9% lower in the obesity trial
Apolipoprotein B (apoB): 21.4% and 24.2% lower
Total LDL particles: 19.7% and 23.5% lower
Small LDL particles: 32.6% and 32.3% lower
Large triglyceride-rich lipoprotein particles: 84.4% and 76.6% lower

ApoB counts the particles that carry cholesterol into artery walls, so it is a useful cross-check on LDL. Two cautions apply. "Up to" means the best-performing dose group, not the average person. And a post hoc analysis was planned after the trial ended, which makes it weaker evidence than a prespecified endpoint.

What did the phase 3 trials report for lipids?

The phase 3 lipid figures available so far come from Eli Lilly press releases. They cover the highest dose studied in each trial at 80 weeks.

TRIUMPH-2 (adults with type 2 diabetes): triglycerides fell 39.5% and non-HDL cholesterol fell 19.6%, according to Lilly's September 29, 2026 release.
TRIUMPH-3 (adults with severe obesity and heart disease): triglycerides fell 37.0% and non-HDL cholesterol fell 16.5%, according to Lilly's July 23, 2026 release.
TRIUMPH-1 (adults with obesity, no diabetes): Lilly's May 2026 release says non-HDL cholesterol and triglycerides improved from baseline. It gives no figures.

Read these numbers with care. The sentences in the releases give average reductions and do not state a placebo figure for these measures. The TRIUMPH-2 release says its data use the "efficacy estimand", which models what would happen if everyone stayed on treatment. That method tends to produce larger numbers than counting every participant.

The releases report non-HDL cholesterol, not LDL cholesterol. So no phase 3 LDL figure is public in the sources we read. Everyone in TRIUMPH-3 had established heart disease. The release does not say how many took statins, or how much of the change came on top of those drugs.

How much does blood pressure fall on retatrutide?

The 2026 meta-analysis found systolic blood pressure fell by 6.79 mmHg (95% CI 5.23 to 8.36) more than in control groups. Diastolic pressure fell by 2.46 mmHg (95% CI 1.67 to 3.25).

The phase 3 press releases report larger systolic drops at the highest dose:

10.8 mmHg in TRIUMPH-2
9.3 mmHg in TRIUMPH-3
14.0 mmHg in TRIUMPH-4, the knee osteoarthritis trial (Lilly, December 2025)

The two sets of figures are not the same kind of number. The meta-analysis shows the gap between retatrutide and control. The press release figures are average reductions, with no placebo figure in the sentences that report them.

A falling blood pressure can go too far. The peer-reviewed TRIUMPH-2 paper in The Lancet listed hypotension (low blood pressure) as an adverse event. It occurred in 1% of the 4 mg group, 5% of the 9 mg group, and 6% of the 12 mg group, versus less than 1% on placebo. That matters most for people who already take blood pressure medicine. Our sister site hypertension.md covers how blood pressure is measured and treated.

Does retatrutide raise heart rate?

Yes, in phase 2. The obesity trial in the New England Journal of Medicine reported dose-dependent increases in heart rate. They peaked at 24 weeks and declined after that.

"Dose-dependent" means higher doses raised heart rate more. The abstract does not give the size of the rise in beats per minute, so we do not quote one here.

The abstracts of the phase 3 TRIUMPH-1 and TRIUMPH-2 papers do not mention heart rate. The Lilly press releases we read do not mention it either. The full papers may report it, but we could not read them. See our retatrutide side effects guide for the wider safety picture.

Which of these numbers are peer reviewed?

The sources fall into two groups.

Peer-reviewed journals:

The phase 2 heart rate finding (NEJM, 2023)
The pooled blood pressure, LDL, total cholesterol, and triglyceride changes (meta-analysis, 2026)
The non-HDL, apoB, and lipoprotein particle changes (post hoc analysis, 2026)
The hypotension rates in TRIUMPH-2 (The Lancet, 2026)

Company press releases only:

The triglyceride, non-HDL cholesterol, and systolic blood pressure figures for TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4

TRIUMPH-1 was published in the New England Journal of Medicine and TRIUMPH-2 in The Lancet, both on September 29, 2026. Their abstracts report weight, pain, sleep apnea, and adverse events. They do not give lipid or blood pressure figures. Those figures may sit in the full text or supplements, which we could not access.

Do better numbers mean fewer heart attacks?

Not yet proven. Lower LDL, lower triglycerides, and lower blood pressure are risk factors moving in a good direction. They are not the same as fewer heart attacks or strokes.

Weight loss also explains part of the change. People in TRIUMPH-2 lost a mean 18.8% of body weight on the highest dose, counting every randomized participant, and weight loss alone lowers blood pressure and triglycerides. The published trials cannot separate a direct drug effect from the effect of losing weight.

The trial built to count heart events is TRIUMPH-Outcomes. Our post on the retatrutide cardiovascular outcome trials explains its design and timeline. For the glucose side of the same trials, see retatrutide and A1C.

The bottom line

Retatrutide lowered LDL cholesterol, total cholesterol, triglycerides, non-HDL cholesterol, apoB, and blood pressure in clinical trials. HDL cholesterol stayed flat. Heart rate rose in a dose-dependent way in phase 2, and low blood pressure was more common than on placebo in TRIUMPH-2.

The phase 2 figures are peer reviewed. The phase 3 lipid and blood pressure figures come from Lilly press releases. No trial has shown that these changes prevent heart attacks or strokes. Retatrutide is not FDA approved, and it is not a substitute for a statin or blood pressure medicine.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Retatrutide is investigational; talk with your clinician before changing any cholesterol or blood pressure treatment.